TALi Digital Limited (TD1.AX) Stock Competitors & Peer Comparison
See (TD1.AX) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Healthcare Information Services Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| TD1.AX | A$0.06 | -21.25% | 3.7M | -3.23 | -A$0.02 | N/A |
| PME.AX | A$200.73 | +6.27% | 20.6B | 87.64 | A$2.25 | +0.31% |
| AYA.AX | A$6.03 | +15.74% | 605.4M | -30.13 | -A$0.18 | N/A |
| CGS.AX | A$2.78 | +0.72% | 472.3M | 29.28 | A$0.09 | +0.72% |
| VHT.AX | A$1.15 | +0.44% | 291.3M | -28.63 | -A$0.04 | N/A |
| ALC.AX | A$0.10 | +4.17% | 127.6M | 279.41 | A$0.00 | N/A |
| ONE.AX | A$0.14 | +0.00% | 127.6M | -6.75 | -A$0.02 | N/A |
| M7T.AX | A$0.29 | -1.69% | 67M | -6.76 | -A$0.04 | N/A |
| SHG.AX | A$0.20 | +11.11% | 61M | -9.50 | -A$0.02 | N/A |
| DOC.AX | A$0.13 | +0.00% | 45.8M | -5.20 | -A$0.02 | N/A |
Stock Comparison
TD1.AX vs PME.AX Comparison July 2026
TD1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TD1.AX stands at 3.7M. In comparison, PME.AX has a market cap of 20.6B. Regarding current trading prices, TD1.AX is priced at A$0.06, while PME.AX trades at A$200.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TD1.AX currently has a P/E ratio of -3.23, whereas PME.AX's P/E ratio is 87.64. In terms of profitability, TD1.AX's ROE is -0.42%, compared to PME.AX's ROE of +0.73%. Regarding short-term risk, TD1.AX is less volatile compared to PME.AX. This indicates potentially lower risk in terms of short-term price fluctuations for TD1.AX.Check PME.AX's competition here
TD1.AX vs AYA.AX Comparison July 2026
TD1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TD1.AX stands at 3.7M. In comparison, AYA.AX has a market cap of 605.4M. Regarding current trading prices, TD1.AX is priced at A$0.06, while AYA.AX trades at A$6.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TD1.AX currently has a P/E ratio of -3.23, whereas AYA.AX's P/E ratio is -30.13. In terms of profitability, TD1.AX's ROE is -0.42%, compared to AYA.AX's ROE of -0.36%. Regarding short-term risk, TD1.AX is less volatile compared to AYA.AX. This indicates potentially lower risk in terms of short-term price fluctuations for TD1.AX.Check AYA.AX's competition here
TD1.AX vs CGS.AX Comparison July 2026
TD1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TD1.AX stands at 3.7M. In comparison, CGS.AX has a market cap of 472.3M. Regarding current trading prices, TD1.AX is priced at A$0.06, while CGS.AX trades at A$2.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TD1.AX currently has a P/E ratio of -3.23, whereas CGS.AX's P/E ratio is 29.28. In terms of profitability, TD1.AX's ROE is -0.42%, compared to CGS.AX's ROE of +0.22%. Regarding short-term risk, TD1.AX is less volatile compared to CGS.AX. This indicates potentially lower risk in terms of short-term price fluctuations for TD1.AX.Check CGS.AX's competition here
TD1.AX vs VHT.AX Comparison July 2026
TD1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TD1.AX stands at 3.7M. In comparison, VHT.AX has a market cap of 291.3M. Regarding current trading prices, TD1.AX is priced at A$0.06, while VHT.AX trades at A$1.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TD1.AX currently has a P/E ratio of -3.23, whereas VHT.AX's P/E ratio is -28.63. In terms of profitability, TD1.AX's ROE is -0.42%, compared to VHT.AX's ROE of -0.18%. Regarding short-term risk, TD1.AX is more volatile compared to VHT.AX. This indicates potentially higher risk in terms of short-term price fluctuations for TD1.AX.Check VHT.AX's competition here
TD1.AX vs ALC.AX Comparison July 2026
TD1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TD1.AX stands at 3.7M. In comparison, ALC.AX has a market cap of 127.6M. Regarding current trading prices, TD1.AX is priced at A$0.06, while ALC.AX trades at A$0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TD1.AX currently has a P/E ratio of -3.23, whereas ALC.AX's P/E ratio is 279.41. In terms of profitability, TD1.AX's ROE is -0.42%, compared to ALC.AX's ROE of +0.04%. Regarding short-term risk, TD1.AX is less volatile compared to ALC.AX. This indicates potentially lower risk in terms of short-term price fluctuations for TD1.AX.Check ALC.AX's competition here
TD1.AX vs ONE.AX Comparison July 2026
TD1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TD1.AX stands at 3.7M. In comparison, ONE.AX has a market cap of 127.6M. Regarding current trading prices, TD1.AX is priced at A$0.06, while ONE.AX trades at A$0.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TD1.AX currently has a P/E ratio of -3.23, whereas ONE.AX's P/E ratio is -6.75. In terms of profitability, TD1.AX's ROE is -0.42%, compared to ONE.AX's ROE of -2.27%. Regarding short-term risk, TD1.AX is less volatile compared to ONE.AX. This indicates potentially lower risk in terms of short-term price fluctuations for TD1.AX.Check ONE.AX's competition here
TD1.AX vs M7T.AX Comparison July 2026
TD1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TD1.AX stands at 3.7M. In comparison, M7T.AX has a market cap of 67M. Regarding current trading prices, TD1.AX is priced at A$0.06, while M7T.AX trades at A$0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TD1.AX currently has a P/E ratio of -3.23, whereas M7T.AX's P/E ratio is -6.76. In terms of profitability, TD1.AX's ROE is -0.42%, compared to M7T.AX's ROE of -0.24%. Regarding short-term risk, TD1.AX is less volatile compared to M7T.AX. This indicates potentially lower risk in terms of short-term price fluctuations for TD1.AX.Check M7T.AX's competition here
TD1.AX vs SHG.AX Comparison July 2026
TD1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TD1.AX stands at 3.7M. In comparison, SHG.AX has a market cap of 61M. Regarding current trading prices, TD1.AX is priced at A$0.06, while SHG.AX trades at A$0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TD1.AX currently has a P/E ratio of -3.23, whereas SHG.AX's P/E ratio is -9.50. In terms of profitability, TD1.AX's ROE is -0.42%, compared to SHG.AX's ROE of -0.60%. Regarding short-term risk, TD1.AX is less volatile compared to SHG.AX. This indicates potentially lower risk in terms of short-term price fluctuations for TD1.AX.Check SHG.AX's competition here
TD1.AX vs DOC.AX Comparison July 2026
TD1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TD1.AX stands at 3.7M. In comparison, DOC.AX has a market cap of 45.8M. Regarding current trading prices, TD1.AX is priced at A$0.06, while DOC.AX trades at A$0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TD1.AX currently has a P/E ratio of -3.23, whereas DOC.AX's P/E ratio is -5.20. In terms of profitability, TD1.AX's ROE is -0.42%, compared to DOC.AX's ROE of +2.51%. Regarding short-term risk, TD1.AX is less volatile compared to DOC.AX. This indicates potentially lower risk in terms of short-term price fluctuations for TD1.AX.Check DOC.AX's competition here
TD1.AX vs BMT.AX Comparison July 2026
TD1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TD1.AX stands at 3.7M. In comparison, BMT.AX has a market cap of 45.1M. Regarding current trading prices, TD1.AX is priced at A$0.06, while BMT.AX trades at A$0.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TD1.AX currently has a P/E ratio of -3.23, whereas BMT.AX's P/E ratio is -7.34. In terms of profitability, TD1.AX's ROE is -0.42%, compared to BMT.AX's ROE of -0.14%. Regarding short-term risk, TD1.AX is more volatile compared to BMT.AX. This indicates potentially higher risk in terms of short-term price fluctuations for TD1.AX.Check BMT.AX's competition here
TD1.AX vs COO.AX Comparison July 2026
TD1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TD1.AX stands at 3.7M. In comparison, COO.AX has a market cap of 26.3M. Regarding current trading prices, TD1.AX is priced at A$0.06, while COO.AX trades at A$0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TD1.AX currently has a P/E ratio of -3.23, whereas COO.AX's P/E ratio is N/A. In terms of profitability, TD1.AX's ROE is -0.42%, compared to COO.AX's ROE of -0.05%. Regarding short-term risk, TD1.AX is more volatile compared to COO.AX. This indicates potentially higher risk in terms of short-term price fluctuations for TD1.AX.Check COO.AX's competition here
TD1.AX vs TRI.AX Comparison July 2026
TD1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TD1.AX stands at 3.7M. In comparison, TRI.AX has a market cap of 24.2M. Regarding current trading prices, TD1.AX is priced at A$0.06, while TRI.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TD1.AX currently has a P/E ratio of -3.23, whereas TRI.AX's P/E ratio is N/A. In terms of profitability, TD1.AX's ROE is -0.42%, compared to TRI.AX's ROE of -0.08%. Regarding short-term risk, TD1.AX is less volatile compared to TRI.AX. This indicates potentially lower risk in terms of short-term price fluctuations for TD1.AX.Check TRI.AX's competition here
TD1.AX vs PKY.AX Comparison July 2026
TD1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TD1.AX stands at 3.7M. In comparison, PKY.AX has a market cap of 23M. Regarding current trading prices, TD1.AX is priced at A$0.06, while PKY.AX trades at A$0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TD1.AX currently has a P/E ratio of -3.23, whereas PKY.AX's P/E ratio is -10.32. In terms of profitability, TD1.AX's ROE is -0.42%, compared to PKY.AX's ROE of -11.22%. Regarding short-term risk, TD1.AX is less volatile compared to PKY.AX. This indicates potentially lower risk in terms of short-term price fluctuations for TD1.AX.Check PKY.AX's competition here
TD1.AX vs EMD.AX Comparison July 2026
TD1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TD1.AX stands at 3.7M. In comparison, EMD.AX has a market cap of 22.9M. Regarding current trading prices, TD1.AX is priced at A$0.06, while EMD.AX trades at A$0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TD1.AX currently has a P/E ratio of -3.23, whereas EMD.AX's P/E ratio is -4.96. In terms of profitability, TD1.AX's ROE is -0.42%, compared to EMD.AX's ROE of -0.52%. Regarding short-term risk, TD1.AX is less volatile compared to EMD.AX. This indicates potentially lower risk in terms of short-term price fluctuations for TD1.AX.Check EMD.AX's competition here
TD1.AX vs RHT.AX Comparison July 2026
TD1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TD1.AX stands at 3.7M. In comparison, RHT.AX has a market cap of 21.5M. Regarding current trading prices, TD1.AX is priced at A$0.06, while RHT.AX trades at A$0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TD1.AX currently has a P/E ratio of -3.23, whereas RHT.AX's P/E ratio is 28.30. In terms of profitability, TD1.AX's ROE is -0.42%, compared to RHT.AX's ROE of +0.08%. Regarding short-term risk, TD1.AX is less volatile compared to RHT.AX. This indicates potentially lower risk in terms of short-term price fluctuations for TD1.AX.Check RHT.AX's competition here
TD1.AX vs PCK.AX Comparison July 2026
TD1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TD1.AX stands at 3.7M. In comparison, PCK.AX has a market cap of 20.3M. Regarding current trading prices, TD1.AX is priced at A$0.06, while PCK.AX trades at A$0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TD1.AX currently has a P/E ratio of -3.23, whereas PCK.AX's P/E ratio is -3.88. In terms of profitability, TD1.AX's ROE is -0.42%, compared to PCK.AX's ROE of -10.10%. Regarding short-term risk, TD1.AX is more volatile compared to PCK.AX. This indicates potentially higher risk in terms of short-term price fluctuations for TD1.AX.Check PCK.AX's competition here
TD1.AX vs VHL.AX Comparison July 2026
TD1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TD1.AX stands at 3.7M. In comparison, VHL.AX has a market cap of 18.4M. Regarding current trading prices, TD1.AX is priced at A$0.06, while VHL.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TD1.AX currently has a P/E ratio of -3.23, whereas VHL.AX's P/E ratio is -0.82. In terms of profitability, TD1.AX's ROE is -0.42%, compared to VHL.AX's ROE of -4.12%. Regarding short-term risk, TD1.AX is less volatile compared to VHL.AX. This indicates potentially lower risk in terms of short-term price fluctuations for TD1.AX.Check VHL.AX's competition here
TD1.AX vs IME.AX Comparison July 2026
TD1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TD1.AX stands at 3.7M. In comparison, IME.AX has a market cap of 17.7M. Regarding current trading prices, TD1.AX is priced at A$0.06, while IME.AX trades at A$0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TD1.AX currently has a P/E ratio of -3.23, whereas IME.AX's P/E ratio is -4.23. In terms of profitability, TD1.AX's ROE is -0.42%, compared to IME.AX's ROE of -0.19%. Regarding short-term risk, TD1.AX is less volatile compared to IME.AX. This indicates potentially lower risk in terms of short-term price fluctuations for TD1.AX.Check IME.AX's competition here
TD1.AX vs 1ST.AX Comparison July 2026
TD1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TD1.AX stands at 3.7M. In comparison, 1ST.AX has a market cap of 15.6M. Regarding current trading prices, TD1.AX is priced at A$0.06, while 1ST.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TD1.AX currently has a P/E ratio of -3.23, whereas 1ST.AX's P/E ratio is -1.10. In terms of profitability, TD1.AX's ROE is -0.42%, compared to 1ST.AX's ROE of +0.69%. Regarding short-term risk, TD1.AX is more volatile compared to 1ST.AX. This indicates potentially higher risk in terms of short-term price fluctuations for TD1.AX.Check 1ST.AX's competition here
TD1.AX vs MDR.AX Comparison July 2026
TD1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TD1.AX stands at 3.7M. In comparison, MDR.AX has a market cap of 14M. Regarding current trading prices, TD1.AX is priced at A$0.06, while MDR.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TD1.AX currently has a P/E ratio of -3.23, whereas MDR.AX's P/E ratio is -0.20. In terms of profitability, TD1.AX's ROE is -0.42%, compared to MDR.AX's ROE of -2.31%. Regarding short-term risk, TD1.AX is less volatile compared to MDR.AX. This indicates potentially lower risk in terms of short-term price fluctuations for TD1.AX.Check MDR.AX's competition here
TD1.AX vs ICR.AX Comparison July 2026
TD1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TD1.AX stands at 3.7M. In comparison, ICR.AX has a market cap of 9M. Regarding current trading prices, TD1.AX is priced at A$0.06, while ICR.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TD1.AX currently has a P/E ratio of -3.23, whereas ICR.AX's P/E ratio is -3.51. In terms of profitability, TD1.AX's ROE is -0.42%, compared to ICR.AX's ROE of +5.38%. Regarding short-term risk, TD1.AX is less volatile compared to ICR.AX. This indicates potentially lower risk in terms of short-term price fluctuations for TD1.AX.Check ICR.AX's competition here
TD1.AX vs OPL.AX Comparison July 2026
TD1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TD1.AX stands at 3.7M. In comparison, OPL.AX has a market cap of 5.4M. Regarding current trading prices, TD1.AX is priced at A$0.06, while OPL.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TD1.AX currently has a P/E ratio of -3.23, whereas OPL.AX's P/E ratio is -2.20. In terms of profitability, TD1.AX's ROE is -0.42%, compared to OPL.AX's ROE of +12.68%. Regarding short-term risk, TD1.AX is more volatile compared to OPL.AX. This indicates potentially higher risk in terms of short-term price fluctuations for TD1.AX.Check OPL.AX's competition here
TD1.AX vs VFX.AX Comparison July 2026
TD1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TD1.AX stands at 3.7M. In comparison, VFX.AX has a market cap of 5.4M. Regarding current trading prices, TD1.AX is priced at A$0.06, while VFX.AX trades at A$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TD1.AX currently has a P/E ratio of -3.23, whereas VFX.AX's P/E ratio is -3.10. In terms of profitability, TD1.AX's ROE is -0.42%, compared to VFX.AX's ROE of +2.45%. Regarding short-term risk, TD1.AX is less volatile compared to VFX.AX. This indicates potentially lower risk in terms of short-term price fluctuations for TD1.AX.Check VFX.AX's competition here
TD1.AX vs MEB.AX Comparison July 2026
TD1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TD1.AX stands at 3.7M. In comparison, MEB.AX has a market cap of 4.5M. Regarding current trading prices, TD1.AX is priced at A$0.06, while MEB.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TD1.AX currently has a P/E ratio of -3.23, whereas MEB.AX's P/E ratio is -0.10. In terms of profitability, TD1.AX's ROE is -0.42%, compared to MEB.AX's ROE of -0.15%. Regarding short-term risk, TD1.AX is less volatile compared to MEB.AX. This indicates potentially lower risk in terms of short-term price fluctuations for TD1.AX.Check MEB.AX's competition here
TD1.AX vs ENL.AX Comparison July 2026
TD1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TD1.AX stands at 3.7M. In comparison, ENL.AX has a market cap of 4.2M. Regarding current trading prices, TD1.AX is priced at A$0.06, while ENL.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TD1.AX currently has a P/E ratio of -3.23, whereas ENL.AX's P/E ratio is -0.17. In terms of profitability, TD1.AX's ROE is -0.42%, compared to ENL.AX's ROE of -1.39%. Regarding short-term risk, TD1.AX is more volatile compared to ENL.AX. This indicates potentially higher risk in terms of short-term price fluctuations for TD1.AX.Check ENL.AX's competition here
TD1.AX vs HIQ.AX Comparison July 2026
TD1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TD1.AX stands at 3.7M. In comparison, HIQ.AX has a market cap of 3M. Regarding current trading prices, TD1.AX is priced at A$0.06, while HIQ.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TD1.AX currently has a P/E ratio of -3.23, whereas HIQ.AX's P/E ratio is -0.44. In terms of profitability, TD1.AX's ROE is -0.42%, compared to HIQ.AX's ROE of +1.53%. Regarding short-term risk, TD1.AX is less volatile compared to HIQ.AX. This indicates potentially lower risk in terms of short-term price fluctuations for TD1.AX.Check HIQ.AX's competition here
TD1.AX vs OAK.AX Comparison July 2026
TD1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TD1.AX stands at 3.7M. In comparison, OAK.AX has a market cap of 1.9M. Regarding current trading prices, TD1.AX is priced at A$0.06, while OAK.AX trades at A$0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TD1.AX currently has a P/E ratio of -3.23, whereas OAK.AX's P/E ratio is N/A. In terms of profitability, TD1.AX's ROE is -0.42%, compared to OAK.AX's ROE of +0.17%. Regarding short-term risk, TD1.AX is more volatile compared to OAK.AX. This indicates potentially higher risk in terms of short-term price fluctuations for TD1.AX.Check OAK.AX's competition here
TD1.AX vs JTL.AX Comparison July 2026
TD1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TD1.AX stands at 3.7M. In comparison, JTL.AX has a market cap of 281.3K. Regarding current trading prices, TD1.AX is priced at A$0.06, while JTL.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TD1.AX currently has a P/E ratio of -3.23, whereas JTL.AX's P/E ratio is -0.10. In terms of profitability, TD1.AX's ROE is -0.42%, compared to JTL.AX's ROE of +0.60%. Regarding short-term risk, TD1.AX is more volatile compared to JTL.AX. This indicates potentially higher risk in terms of short-term price fluctuations for TD1.AX.Check JTL.AX's competition here
TD1.AX vs TTB.AX Comparison July 2026
TD1.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TD1.AX stands at 3.7M. In comparison, TTB.AX has a market cap of 267.4K. Regarding current trading prices, TD1.AX is priced at A$0.06, while TTB.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TD1.AX currently has a P/E ratio of -3.23, whereas TTB.AX's P/E ratio is -0.02. In terms of profitability, TD1.AX's ROE is -0.42%, compared to TTB.AX's ROE of -1.05%. Regarding short-term risk, TD1.AX is more volatile compared to TTB.AX. This indicates potentially higher risk in terms of short-term price fluctuations for TD1.AX.Check TTB.AX's competition here